Compare BSET & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSET | IMUX |
|---|---|---|
| Founded | 1902 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.2M | 155.8M |
| IPO Year | 1995 | 2013 |
| Metric | BSET | IMUX |
|---|---|---|
| Price | $21.67 | $6.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $43.09 |
| AVG Volume (30 Days) | 26.3K | ★ 417.3K |
| Earning Date | 09-30-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | ★ 163.06 | 38.00 |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $456,855,000.00 | N/A |
| Revenue This Year | $0.85 | N/A |
| Revenue Next Year | $3.42 | N/A |
| P/E Ratio | $35.15 | ★ N/A |
| Revenue Growth | ★ 0.96 | N/A |
| 52 Week Low | $13.17 | $0.51 |
| 52 Week High | $22.26 | $17.43 |
| Indicator | BSET | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 28.28 |
| Support Level | $14.03 | $0.83 |
| Resistance Level | $22.26 | $8.60 |
| Average True Range (ATR) | 0.95 | 0.69 |
| MACD | 0.18 | 0.04 |
| Stochastic Oscillator | 85.15 | 17.84 |
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.